天新药业: 信息披露暂缓与豁免管理制度

Core Viewpoint - The article outlines the information disclosure management system of Jiangxi Tianxin Pharmaceutical Co., Ltd., emphasizing the importance of protecting national secrets and commercial confidentiality while ensuring compliance with relevant laws and regulations [2][4]. Group 1: General Principles - The company establishes this system to regulate the deferral and exemption of information disclosure, ensuring compliance with the Company Law, Securities Law, and other relevant regulations [2]. - The company is responsible for determining whether information can be deferred or exempted from disclosure based on specific criteria [2][3]. Group 2: Scope of Deferred and Exempted Information - Information that involves national secrets or could violate confidentiality regulations may be exempted from disclosure [2][3]. - Commercial secrets can be deferred or exempted from disclosure if they meet certain conditions, such as being core technology information that could lead to unfair competition [2][3]. Group 3: Review Procedures for Deferral and Exemption - Individuals aware of the information must limit its disclosure to a minimum number of people until a decision is made regarding deferral or exemption [3]. - The company must maintain a record of any deferred or exempted information, including the type of report and the reasons for deferral or exemption [3][4]. Group 4: Responsibilities and Penalties - The company will impose penalties on individuals responsible for failing to disclose information that should have been disclosed after the reasons for deferral or exemption have ceased [4][5]. - The company must ensure that all information provided for deferral or exemption is truthful, accurate, and complete [4].